Cardiff, Wales – Valley Diagnostics Ltd., a Welsh diagnostics company commercialising next-generation point-of-care lateral flow tests (LFTs), has signed several licencing agreements with its research partner and collaborator Aberystwyth University to bring to market innovative diagnostic tests that will revolutionise disease detection. The agreements grant Valley Diagnostics exclusive global rights to patented-protected biomarkers in four application areas including prostate cancer, lung cancer, bovine tuberculosis (bTB), and paratuberculosis (paraTB), also known as Johne’s disease.
Under the terms of the agreement, Valley Diagnostics will leverage its knowledge and expertise in commercialising healthcare products and digital technology to commercialise LFTs that can identify human and animal disease biomarkers, allowing for early detection and diagnosis of diseases. The partnership is expected to significantly change the diagnostic testing market especially in prostate cancer and bTB where current testing methods are not accurate, expensive and have long turnaround times. bTB is one of the most pressing animal health problems in the UK, costing the industry £150 million a year,[i] similarly prostate cancer has now become the most prevalent cancer among men with more than 56,000 diagnoses every year.[ii]
The signing of the licencing agreements allows Valley Diagnostics to continue its mission for earlier detection and diagnosis of disease, helping to open the doors to longer, healthier and happier lives.
Valley Diagnostics is developing an innovative, highly accurate test method that can identify a range of disease-causing biomarkers from a single sample of urine. The company's innovative biomarker fingerprint lateral flow approach offers a simple, easy-to-use, and inexpensive way to diagnose diseases with up to 95% accuracy.* Backed by an expert advisory board with extensive experience in respiratory medicine, oncology and metabolomics, Valley Diagnostics is poised to transform disease diagnosis.
“We’re grateful to partner with Aberystwyth University to help bring our innovative solutions to those who need them most,” said Dave Taylor, CEO of Valley Diagnostics. “The knowledge and understanding of the pioneering scientists in biomarker discovery at the university has been crucial to getting us to this point. The next stage is to get the LFT kits into production which we then hope to roll out in 2026. This brings us one step closer to simple, inexpensive, easy-to-use and accurate disease detection.”
“As a partner of Valley Diagnostics, we’re excited to enter into this licencing agreement that will enable better and more accurate disease detection and diagnosis to be brought to market,” said Professor Luis Mur at Aberystwyth University. “We look forward to continuing our collaboration into the future.”
The agreement is effective immediately.
For more information on Valley Diagnostics, visit https://www.valleydiagnostics.co.uk/ to get in touch.
*Data on file at Valley Diagnostics.